SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community members intensely debate Donald Trump's recent State of the Union address, fueling highly polarized opinions regarding his economic claims and the political implications for his media company.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending amidst a battle between bullish enthusiasm for its reported $8.5 billion Meta-backed loan for AI infrastructure expansion and bearish concerns over its credit profile after reports of difficulty securing financing for another data center, a claim the company denies. The market is sharply divided ahead of upcoming earnings, with many anticipating a significant AI-driven rally while others fear potential debt-related headwinds, also closely watching NVIDIA's sector-influencing report.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending following its Q4 earnings, which revealed a wider-than-expected loss despite revenue beating estimates, alongside news of a 12% workforce reduction and concerns over future share dilution. The community is heavily discussing the company's high cash burn, its challenging path to profitability, and the lack of a permanent CEO, while some optimists point to revenue growth and institutional investor interest as potential positives.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

WEEDCOIN CRYPTO is trending as its community anticipates momentum around the upcoming '4/20' period, actively promoting it as a 'culture coin' on Solana for the global cannabis community. Discussions highlight its long-term vision and the broader potential of cannabis, citing recent research and policy developments, despite some skepticism about volatility.

Pieverse

PIEVERSE CRYPTO is trending due to reports of a significant short squeeze and liquidations, coupled with observations of quiet accumulation. The community is actively discussing PIEVERSE's distinction as the "true pie universe" amidst broader concerns around "Pi Coin" scams.

FIST is the governance token of FstSwap, a decentralized exchange protocol based on BSC Binance Smart Chain, with a total of 200 million tokens in full circulation

Fistbump

FIST CRYPTO is trending as it's being heavily tagged alongside promotional messages for the newly launched MIGA token, with the community actively discussing an immediate airdrop opportunity for those who purchase MIGA.

MEFAI is an institutional-grade trading intelligence system leveraging AI to process high-frequency data streams from on-chain activity, derivatives markets, order book depth, and behavioral sentiment. It delivers real-time structural market bias signals for strategic decision-making. Designed for professionals, MEFAI eliminates emotional bias and provides a transparent, rules-based edge in modern algorithmic environments.

META FINANCIAL AI

MEFAI is trending as community discussions revolve around the launch and rapid promotion of a new token, MIGA, with users actively participating in airdrop incentives and highlighting its initial momentum, while also mentioning MEFAI itself as a low-cap prospect.

Binance Coin is the cryptocurrency of the Binance platform. It is a trading platform exclusively for cryptocurrencies. The name "Binance" is a combination of binary and finance.  Thus, the startup name shows that only cryptocurrencies can be traded against each other. It is not possible to trade crypto currencies against Fiat. The platform achieved an enormous success within a very short time and is focused on worldwide market with Malta headquarters. The cryptocurrency currently has a daily trading volume of 1.5 billion - 2 billion US dollars and is still increasing.  In total, there will only be 200 million BNBs. Binance uses the ERC20 token standard from Ethereum and has distributed it as follow: 50% sold on ICO, 40% to the team and 10% to Angel investors. The coin can be used to pay fees on Binance. These include trading fees, transaction fees, listing fees and others. Binance gives you a huge discount when fees are paid in BNB.   The schedule of BNB fees discount is as follow: In the first year, 50% discount on all fees, second year 25% discount, third year 12.5% discount, fourth year 6.75 % discount, and from the fifth year onwards there is no discount. This structure is used to incentivize users to buy BNB and do trades within Binance.  Binance announced in a buyback plan that it would buy back up to 100 million BNB in Q1 2018. The coins are then burned. This means that they are devaluated to increase the value of the remaining coins. This benefits investors. In the future, the cryptocurrency will remain an asset on the trading platform and will be used as gas.  Other tokens that are issued by exchanges include Bibox Token, OKB, Huobi Token, and more.

Binance

BNB is actively discussed for its expansion into tokenized stock products and new institutional integrations for off-exchange collateral, signaling a deeper push into traditional finance. However, significant community skepticism persists amid allegations of market manipulation and ongoing regulatory challenges for the exchange.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is actively discussed due to a potential short squeeze, fueled by Tether's increasing ownership and substantial investment commitments for advertising and cloud services, alongside its strategic acquisition of Northern Data for AI infrastructure and the rollout of its 'Rumble Shorts' feature.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending amid robust community discussion around its ANKTIVA cancer treatment and intense short squeeze speculation, fueled by ongoing international regulatory progress and anticipation of further corporate developments. Investors are highly optimistic about the company's scientific advancements and its potential global market impact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief...

HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual...

Credit-Card Sized Device Wins FDA Clearance for At-Home Heart Monitoring

Cardiac care is undergoing a fundamental shift as technology enables patients to capture critical health data outside traditional medical settings. The ability to record meaningful cardiac information during symptomatic episodes, rather than hours or days later in a doctor's office, represents a paradigm change in how physicians diagnose and manage heart conditions affecting millions of Americans.Shares of HeartBeam, Inc. (NASDAQ: BEAT) are surging Wednesday after the company announced FDA 510(k) clearance for its groundbreaking 12-lead electrocardiogram (ECG) synthesis software for ...

<ul class="summary-bullets"><li>The clearance enables HeartBeam’s cable-free technology to capture the heart’s electrical signals in three dimensions.</li><li>The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination.</li><li>The company intends to roll out a controlled commercial launch in early 2026.</li></ul>HeartBeam, Inc. (BEAT) on Wednesday announced that the U.S. Food and Drug Administration (FDA) has cleared its 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment, which enables its cable-free technology to capture the heart’s electrical signals in three dimensions and convert them into a complete 12-lead ECG.The approval follows a successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a significant milestone for the company.<h2 class="st-heading-2">Why It Matters?</h2>Unlike traditional single-lead or 6-lead devices, this innovation allows patients to obtain accurate cardiac readings from home, with synthesized results promptly reviewed by board-certified cardiologists.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/BEAT">HeartBeam’s stock</a> traded over 72% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day, while message volume shifted to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<blockquote>“We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening and prediction algorithms trained on our unique longitudinal data.”-Robert Eno, CEO, HeartBeam</blockquote><h2 class="st-heading-2">Limited U.S. Launch Planned</h2>The company intends to roll out a controlled commercial launch in early 2026, targeting select concierge and preventive cardiology groups that have expressed strong interest.&nbsp;It has developed a working prototype of an extended-wear 12-lead ECG patch, designed to provide continuous cardiac monitoring. As HeartBeam’s 3D ECG platform adoption grows, the resulting data repository will enable longitudinal analysis. The company plans to use this data to develop AI-based screening and predictive algorithms.BEAT stock has lost over 64% in 2025 and over 73% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-signals-tough-road-ahead-amid-slumping-ev-demand-ceo-says-there-is-a-slowdown-there-s-no-question-about-it/cLIHRZWRENx">Lucid Signals Tough Road Ahead Amid Slumping EV Demand: CEO Says ‘There Is A Slowdown, There’s No Question About It’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Atrial tachycardia electrocardiogram, heart rhythm disorder where the patient complains of rapid palpitation sensations.

Why Did BEAT Stock Rocket 72% In Pre-Market Today? 

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.

Equity

The FDA has cleared HeartBeam’s 12-lead electrocardiogram synthesis software for arrhythmia assessment.


What's Behind HeartBeam's Over 40% After-Hours Surge?

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.read more...

HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced its regulatory strategy following...

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

HeartBeam Reports Third Quarter 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operational results for...

HeartBeam Earnings Preview

HeartBeam to Host Third Quarter 2025 Results Conference Call on Thursday, November 13, 2025 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, November 13...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

HeartBeam Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$1.42
Prev Close	$1.40
Open	$1.39
Dividend Yield	0.00%
50-Day Moving Average	$2.03
Beta	1.24
Avg. Volume	1.19M
PE Ratio	-2.11

52-Week High	$4.00
52-Week Low	$0.54
Market Capitalization	$56.16M
EPS (Annual)	-$0.7299
Price to Book	118.44
Revenue Per Employee	$0.00

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc